Madrigal Pharmaceuticals
MDGL · NASDAQ
Bulios Fair Price
$646.98
25.2% upside
Current Price
$516.56
According to Bulios Fair Price, MDGL is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Madrigal Pharmaceuticals, Inc. is an American biotechnology company focused on developing new therapeutic drugs for liver and cardiometabolic diseases. The company specializes in research and development of drugs aimed at improving liver health, particularly in relation to non-alcoholic steatohepatitis (NASH) and cirrhosis. Madrigal Pharmaceuticals is known for its innovative technology targeting selective activation of liver receptors, which has the potential to provide effective therapeutic options for patients suffering from these complex and difficult-to-treat conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
William J. Sibold
Employees
915
Headquarters
West Conshohocken
Upcoming events
Earnings
Upcoming earnings report